论文部分内容阅读
目的分析促红细胞生成素对慢性心功能不全合并贫血患者的疗效及安全性。方法将2012年2月至2015年3月期间收治于我院的慢性心功能不全合并贫血患者92例为研究对象,采用电脑分组法将其均分成观察组46例以及对照组46例。其中对照组患者给予传统常规抗心力衰竭联合铁剂抗贫血方式治疗。观察组患者采用促红细胞生成素治疗。对比分析两组患者的治疗效果和安全性。结果与对照组患者相比,观察组患者治疗后Hb(血红蛋白)、RBC(红细胞)、SV(每搏输出量)、CO(心输出量)等各项指标得到明显上升,同时得到有效改善(P<0.05)差异具备统计学意义。结论在对慢性心功能不全合并贫血患者进行治疗的过程中,选择采用促红细胞生成素治疗能够有效改善患者的心功能情况,提升整体的治疗效果,具有较高的安全性,临床中值得推广使用。
Objective To analyze the efficacy and safety of erythropoietin in patients with chronic heart failure and anemia. Methods 92 patients with chronic heart failure and anemia who were admitted to our hospital from February 2012 to March 2015 were divided into observation group (46 cases) and control group (46 cases) by computer. The control group of patients given traditional conventional anti-heart failure combined with iron anti-anemia treatment. Patients in the observation group were treated with erythropoietin. Comparative analysis of two groups of patients with treatment and safety. Results Compared with the control group, the indexes of Hb (hemoglobin), RBC (erythrocyte), SV (stroke volume) and CO (cardiac output) in the observation group were significantly increased at the same time P <0.05) The difference was statistically significant. Conclusion In the treatment of patients with chronic heart failure and anemia, the choice of erythropoietin therapy can effectively improve the patient’s cardiac function and improve the overall treatment effect, with high safety, it is worth to promote the use of the clinic .